GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (FRA:0RY) » Definitions » Operating Margin %

Rhythm Biosciences (FRA:0RY) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Rhythm Biosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Rhythm Biosciences's Operating Income for the six months ended in Dec. 2023 was €-1.70 Mil. Rhythm Biosciences's Revenue for the six months ended in Dec. 2023 was €0.00 Mil. Therefore, Rhythm Biosciences's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Rhythm Biosciences's Operating Margin % or its related term are showing as below:


FRA:0RY's Operating Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -6.08
* Ranked among companies with meaningful Operating Margin % only.

Rhythm Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Rhythm Biosciences's Operating Income for the six months ended in Dec. 2023 was €-1.70 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.82 Mil.


Rhythm Biosciences Operating Margin % Historical Data

The historical data trend for Rhythm Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Operating Margin % Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
Get a 7-Day Free Trial - - - - -

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rhythm Biosciences's Operating Margin %

For the Diagnostics & Research subindustry, Rhythm Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's Operating Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Operating Margin % falls into.



Rhythm Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Rhythm Biosciences's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-7.15 / 0
= %

Rhythm Biosciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-1.701 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (FRA:0RY) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Rhythm Biosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (FRA:0RY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (FRA:0RY) Headlines

No Headlines